Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sage Therapeutics, Inc. - Common Stock
(NQ:
SAGE
)
6.890
+0.280 (+4.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sage Therapeutics, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another
August 07, 2023
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with
Via
Benzinga
Wayfair To Rally Over 32%? Here Are 10 Other Analyst Forecasts For Monday
August 07, 2023
Needham raised the price target for MACOM Technology Solutions Holdings, Inc. (NASDAQ: MTSI) from $65 to $84. Needham analyst Quinn Bolton maintained a Buy rating. MACOM Technology shares rose 0.1% to...
Via
Benzinga
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
August 07, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023
August 04, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
What 10 Analyst Ratings Have To Say About Sage Therapeutics
July 27, 2023
Via
Benzinga
Expert Ratings for Sage Therapeutics
May 09, 2023
Via
Benzinga
Sage Therapeutics's Earnings Outlook
May 01, 2023
Via
Benzinga
What 5 Analyst Ratings Have To Say About Sage Therapeutics
March 09, 2023
Via
Benzinga
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
August 04, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
July 31, 2023
Via
Benzinga
Why Sage Therapeutics Stock Is Tumbling Today
July 26, 2023
A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today.
Via
The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
July 26, 2023
Via
Benzinga
Earnings Scheduled For February 16, 2023
February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
July 27, 2023
Via
Benzinga
Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 05, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Why Universal Health Services Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 26, 2023
Gainers Silicon Motion Technology Corporation (NASDAQ: SIMO) shares climbed 78.9% to $93.40 following a report suggesting China approval of the company's Maxlinear merger.
Via
Benzinga
Sage Therapeutics to Present at Upcoming May Investor Conferences
May 03, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
May 02, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
April 18, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the Stifel 2023 CNS Days
March 22, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Appoints Jessica Federer to Board of Directors
March 16, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone
March 13, 2023
Via
Benzinga
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 13, 2023
Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023
March 13, 2023
Via
Benzinga
Illumina, Seagen And Other Big Stocks Moving Higher On Monday
March 13, 2023
U.S. stocks traded slightly lower, with the Nasdaq Composite dropping around 0.2% on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
March 08, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
February 28, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
February 22, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
February 16, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'
February 06, 2023
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.